CONTACT US
SITE MAP
JAPANESE
HOME
About us
Our business model
Investors
Newsroom
TOPへ
A message from the President
About Sosei Group
The story behind our name
Corporate overview
Locations
Our mission and vision
Corporate governance
Management team
Our history
Group companies
TOPへ
Business model
Heptares GPCR drug discovery
Jitsubo peptide technologies
Products and pipeline
Seebri®/NVA237
Ultibro®/QVA149
NorLevo® 0.75mg
SO-1105
Our partners
TOPへ
Our philosophy and strategy
Mid-term financial forecast
Business and Operational Risks
Disclosure policy
Financial information
Financial highlights
Financial data
Reports and presentations
Financial reports
Presentation material and webcasts
Securities Report
Corporate Profile
Shareholder information
Share information
Annual General Meeting
Share price analysis
Share ownership
Analyst coverage
News alerts
Disclaimer
TOPへ
NEWS
Events
Multimedia centre
CLOSE
HOME
Site map
Site map
About us
A message from the President
About Sosei Group
The story behind our name
Corporate overview
Locations
Our mission and vision
Corporate governance
Management team
Our history
Group companies
Our business model
Business model
Heptares GPCR drug discovery
Jitsubo peptide technologies
Products and pipeline
Seebri®/NVA237
Ultibro®/QVA149
NorLevo® 0.75mg
SO-1105
Our partners
Investors
Our philosophy and strategy
Mid-term financial forecast
Business and Operational Risks
Disclosure policy
Financial information
Financial highlights
Financial data
Reports and presentations
Financial reports
Presentation material and webcasts
Securities Report
Corporate Profile
Shareholder information
Share information
Annual General Meeting
Share price analysis
Share ownership
Analyst coverage
News alerts
Disclaimer
Newsroom
NEWS
Events
Multimedia centre
Contact us
Privacy policy
Terms of use
